6Treatment of early rheumatoid arthritis
Section snippets
Rationale for aggressive therapy
Rheumatoid arthritis (RA) is a significant cause of disability, functional loss1 and increased mortality.2., 3. However, many clinicians believe the prognosis is improving with the growing repertoire of disease-modifying antirheumatic drugs (DMARDs) and more aggressive approaches to therapy. The new DMARDs expand treatment options. The approval of leflunomide, the tumour necrosis factor (TNF)-α blockers (etanercept, infliximab, adalimumab), and the interleukin-1 (IL-1) receptor antagonist,
Finding the best DMARD strategy: prospects for early intervention
Finding the best DMARD treatment for early RA is a multi-faceted issue. The appropriate timing of early treatment is uncertain and the so-called ‘window of opportunity’ remains only a theoretical concept.13 Diagnostic and prognostic uncertainties in the early symptomatic stages of RA must be appropriately balanced with the potential damaging consequences of delaying therapy. If urgency is critical to effective management of early RA, then patients with recent-onset arthritis must gain ready
Definition of early RA
While the 1987 American College of Rheumatology (ACR) classification criteria for RA16 allow for a uniform definition of established disease, they do not serve the same purpose in the early symptomatic stages. Classification criteria currently do not exist for early RA, and with a disease duration of <12 months, the current ACR criteria are relatively insensitive for identifying patients who ultimately will develop persistent, erosive disease.17 Inflammatory arthritis that cannot be classified
Early versus delayed DMARD therapy
Only a few studies have been specifically designed to compare the potential benefits of early DMARD therapy with a more deliberate, or delayed, approach (see Table 1). To this end, van der Heide et al performed a 12-month open randomized trial comparing the outcomes of patients who began treatment with a non-steroidal anti-inflammatory drug (NSAID) with those who were initially treated with a DMARD.19 The study included 238 patients with RA whose duration of disease was less than 12 months and
Head-to-head comparisons: Is any DMARD better than another?
Although the evidence calls for prompt initiation of DMARD therapy in the early stages of RA, uncertainty remains about the best DMARD or combination to use in this situation. In clinical practice, methotrexate is often the DMARD of first choice for patients with moderate-to-severe disease. Sulphasalazine is another frequently chosen agent. Hydroxychloroquine may be considered for initial treatment of patients with mild disease. However, which DMARD, if any, to use in the individual patient is
Combination DMARD therapy
Mounting evidence indicates that combination DMARD therapy can produce greater clinical efficacy than DMARD monotherapy without substantially increasing toxicity.37., 38., 39., 40., 41., 42., 43. A few studies have investigated the potential value of combination therapy in early disease (see Table 2). In the FIN-RACo (Finish Rheumatoid Arthritis Combination Therapy) trial, 195 patients with recent-onset RA (median duration 6 months) were randomized to receive a combination of sulphasalazine,
Corticosteroids
Daily oral corticosteroids in doses of 5–10 mg/day have been used primarily for symptomatic control of RA. In a meta-analysis, Saag et al found that treatment with low doses of oral corticosteroids improves various measures of disease activity.49 The extent of clinical efficacy was nearly equivalent to that of some of the conventional DMARDS, such as methotrexate and sulphasalazine. Thus, low doses of oral corticosteroids can control synovitis to a clinically significant degree and are useful
Whom do we treat aggressively?
Although physicians may agree about the value of starting DMARD therapy in the early stages of RA, they would probably debate the urgency of intervention and the question of which patient, if any, should be treated aggressively at the outset of disease. By the time a patient reaches a rheumatologist, many already have persistent synovitis and are functioning suboptimally in their home or work environment. The course of the disease shows considerable variability. Some patients with RA may have
Recommendations
Questions about the best DMARD therapy for early RA cannot be resolved with the current evidence. Some consensus has been reached on the positive value of early introduction of DMARD therapy, and increasing evidence suggests that combination therapy at this stage can produce long-lasting benefits on radiological outcomes. However, well-designed studies have not clarified the relative value of beginning with single or combination DMARD therapy. Presently, most patients with early RA who have
Summary
Effective early treatment of RA depends on prompt diagnostic evaluation and initiation of appropriate DMARD therapy. Treatment decisions are made with the knowledge that early inflammatory arthritis can spontaneously remit or persist with or without a destructive component. Importantly, the disease evolves rapidly to a destructive phenotype in a substantial proportion of patients with RA, providing much of the rationale for early aggressive therapy. However, prognostic information is not
References (65)
- et al.
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
The Lancet
(1999) - et al.
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
The Lancet
(1997) - et al.
Long-term outcome of treating rheumatoid arthritis: results after 20 years
The Lancet
(1987) - et al.
Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years
Arthritis & Rheumatism
(1984) - et al.
Mortality in rheumatoid arthritis: have we made an impact in 4 decades?
Journal of Rheumatology
(1999) - et al.
Cause and age of death in a prospective study of 100 patients with rheumatoid arthritis
Annals of the Rheumatic Diseases
(1981) - et al.
How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS)
Rheumatology
(2000) - et al.
Elucidation of the relationship between synovitis and bone damage. A randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis
Arthritis & Rheumatism
(2003) - et al.
for the COBRA Trial Group. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis
Arthritis & Rheumatism
(2001) Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease
Journal of Rheumatology
(1989)